Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE The APOE-locus association with behavioural variant frontotemporal dementia indicates its potential risk-increasing role across different neurodegenerative diseases, whereas the novel genetic associations of ARHGAP35 and SERPINA1 with progressive non-fluent aphasia point towards a potential role of the stress-signalling pathway in its pathophysiology. 28387812 2017
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. 19164761 2009
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE Furthermore, a strong increase in the APOE epsilon4 allele frequency was found in the FTD population, as 52% were epsilon4 carriers, compared to 21% of the controls. 11259129 2001
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE A penetrance analysis for APOE ε4 genotype in the FTD series identified 14 features for discrimination analysis. 24359501 2014
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE In most non-AD dementias, amyloid positivity increased with both age (from 60 to 80 years) and APOE ε4 carriership (dementia with Lewy bodies: carriers [n = 16], 63% [95% CI, 48%-80%] at 60 years to 83% [95% CI, 67%-92%] at 80 years; noncarriers [n = 18], 29% [95% CI, 15%-50%] at 60 years to 54% [95% CI, 30%-77%] at 80 years; frontotemporal dementia: carriers [n = 48], 19% [95% CI, 12%-28%] at 60 years to 43% [95% CI, 35%-50%] at 80 years; noncarriers [n = 160], 5% [95% CI, 3%-8%] at 60 years to 14% [95% CI, 11%-18%] at 80 years; vascular dementia: carriers [n = 30], 25% [95% CI, 9%-52%] at 60 years to 64% [95% CI, 49%-77%] at 80 years; noncarriers [n = 77], 7% [95% CI, 3%-18%] at 60 years to 29% [95% CI, 17%-43%] at 80 years. 25988463 2015
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE APOE and modulation of Alzheimer's and frontotemporal dementia. 15036621 2004
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE The ApoE ε4 allele frequency was significantly increased among patients in the AD and FTD groups compared with controls. 23887281 2013
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE Meta-analysis across two independent FTD cohorts revealed a genome-wide signal within the APOE region (rs6857, 3'-UTR=PVRL2, p=2.21×10<sup>-12</sup>), and a suggestive signal for rs1358071 within the MAPT region (intronic=CRHR1, p=4.91×10<sup>-7</sup>) with the effect allele tagging the H1 haplotype. 27899424 2017
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE APOE varepsilon4 allele, Tau H2 haplotype and behavioral variant FTD phenotype were associated with worse prognosis over time. 18495299 2010
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE We found no association between PGRN polymorphisms, APOE and microtubule-associated protein tau genotypes, and age at onset of the disease; whereas we report evidence for an association between PRNP codon 129 polymorphism and age at onset of disease in frontotemporal dementia-PGRN(+) patients. 20711061 2011
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE Significant associations with FTD were observed for genotypes rs449647 A/T (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.0-4.5), rs769446 T/C (OR, 4.4; 95% CI, 1.9-10.2), and APOE ε3/ε4 (OR, 4.1; 95% CI, 1.6-10.9). 21555637 2011
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE This study of the largest series of patients with FTD confirms the primary role of tau in FTD and establishes that the H1 haplotype of the tau gene and the E2 allele of APOE interact by an unknown mechanism that increases the risk of FTD. 12056929 2002
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE No difference in the distribution of the tau H1 and H2 haplotypes between FTD cases and controls was observed, whereas the ApoE epsilon4 allele was more frequent in FTD cases. 16157749 2005
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE C9ORF72 repeat expansions have a primary role in increasing the risk of cognitive impairment in patients with ALS; the APOE ε2 allele, to a lesser extent, also increases the risk of FTD. 26903389 2016
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE In addition, the finding in the stage 1 sample that AD risk is significantly influenced by the interaction of APOE with rs1595014 in TMEM106B (P=1·6 × 10(-7)) is noteworthy, because TMEM106B variants have previously been associated with risk of frontotemporal dementia. 25778476 2016
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE We conclude that ApoE4 accelerates neurodegeneration in FTD patients with <i>MAPT</i> mutations or FTLD-tau pathology, independent of Aβ. 30949567 2019
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE Our objective was to determine whether APOE is a risk factor of FTD, using the largest series of patients with FTD and controls analysed so far (94 unrelated patients and 392 age and sex-matched controls), and a meta-analysis. 12107813 2002
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE However, the APOE epsilon 4 allele frequency was not significantly increased in FTD (0.18; n=49), VD (0.10; n=20) or in Lewy body disease without concomitant AD changes (0.13; n=12). 12719629 2003
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 AlteredExpression disease BEFREE A further analysis comparing FTD subgroups revealed slightly lower levels of proteins apolipoprotein E, CD166, osteopontin, transthyretin, and cystatin C in the GRN group (n = 9) compared to the C9orf72 group (n = 7). 30292090 2018
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE The role of apolipoprotein E (ApoE) in FTD is uncertain, though an established risk factor in Alzheimer's disease. 28888721 2017
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. 9213069 1997
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 Biomarker disease BEFREE We thus propose that this extended tau haplotype in combination with apoE epsilon4 is a genetic risk factor for FTD. 11303757 2001
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation disease BEFREE Here we have investigated the frequency of the epsilon4 allele of the Apolipoprotein (APOE) gene in FTD and in other non-Alzheimer forms of dementia related to FTD such as Motor Neurone disease dementia, semantic dementia, progressive aphasia, progressive supranuclear palsy, and corticobasal degeneration. 10833320 2000
Entrez Id: 351
Gene Symbol: APP
APP
0.060 Biomarker disease BEFREE We screened 37 AD, 8 mild cognitive impairment (MCI), 3 AD and CVD (cerebrovascular disease), 3 MCI and CVD, 8 frontotemporal dementia (FTD) and 2 progressive supranuclear palsy (PSP) patients, and 28 normal controls (NCs).We sequenced PSEN1, PSEN2 and APP (EOAD risk factors), as well as MAPT, GRN and TARDBP for all cases and NCs, and analysed the APOE, CLU, CR1 and PICALM genotypes as well as the MAPT and ACE haplotypes (LOAD risk factors) for the AD (n = 37) and AD + MCI (n = 45) cases and NCs (n = 28).We identified variants in PSEN1, PSEN2 and TARDBP across a range of phenotypes (AD, AD and CVD, FTD and PSP), suggesting that screening of all known candidate genes of Alzheimer's and non-Alzheimer's forms of dementias in all dementia cases might be warranted. 26159191 2015
Entrez Id: 351
Gene Symbol: APP
APP
0.060 AlteredExpression disease BEFREE The lowest sAPPβ levels and sAPPβ/YKL-40 ratio were found in the FTD group. 30291183 2018